Prescriber’s Guide: Stahl’s Essential Psychopharmacology 8th Edition by Stephen M. Stahl (2024)

Prescriber’s Guide: Stahl’s Essential Psychopharmacology, 8th Edition (2024) by Stephen M. Stahl ??? an Amazon #1 Bestseller in Mental Health ??? is the world’s bestselling formulary in its field. Published by Cambridge University Press, this trusted reference has been the go-to prescribing companion for psychiatrists, advanced practice psychiatric nurses, primary care clinicians, and pharmacists managing mental health treatments for nearly two decades.
With the range of therapeutic options expanding and the uses of existing treatments diversifying, the eighth edition delivers comprehensive, evidence-based coverage of the full formulary. The new edition features seven brand-new compounds as well as information about several newly approved formulations of existing treatments. Many important new indications are covered for existing entries, alongside updates to the profiles of the entire content and collection ??? including new injectable and transdermal formulations, as well as updated warnings and indications. The icons and Pearls have been refreshed throughout.
With its easy-to-use, full-color, template-driven navigation system, Prescriber’s Guide combines evidence-based data with clinically informed advice to support everyone who is prescribing in the field of mental health.
Each entry includes: therapeutics ??? brand names and generic names, classes, indications, off-label uses; mechanism of action; dosing and use ??? usual dosage range, available forms, dosing tips, overdose; special populations ??? renal/hepatic impairment, cardiac, elderly, children/adolescents, pregnancy/breastfeeding; pearls ??? the art of clinical practice; warnings, side effects, monitoring, interactions, contraindications; and what to expect including onset of action and duration of treatment.
Therapeutic classes covered: antidepressants (SSRIs, SNRIs, atypical, MAOIs, tricyclics, ketamine and esketamine); mood stabilizers (lithium, anticonvulsant mood stabilizers); antipsychotics (first- and second-generation, including LAIs); anxiolytics and hypnotics; ADHD treatments and stimulants; cognitive enhancers and dementia treatments; opioid use disorder treatments; alcohol use disorder treatments; tobacco use disorder treatments; and emerging therapeutics including novel mechanisms.
Essential for: psychiatrists and psychiatry residents; psychiatric mental health nurse practitioners (PMHNP); primary care physicians, internists, and family medicine clinicians; physician assistants; pharmacists practicing in mental health; and any prescriber managing psychiatric treatments.